D.L. BRUMMER, M.D.
This content is PDF only. Please click on the PDF icon to access.
In 1967 surveillance teams at the Center for Disease Control noted that the reported incidence of isoniazidassociated liver disease in a population receiving preventive therapy with isoniazid was higher than that reported in early large group trials. This fact was brought to the attention of the Tuberculosis Control Advisory Committee and the Therapy Committee of the American Thoracic Society. At that time, because of the large number of patients on preventive therapy, it was thought that the liver disease being seen was no more than might be expected in a population of this size. In 1969 Scharer and Smith (1)
BRUMMER D. Isoniazid and Liver Disease. Ann Intern Med. 1971;75:643–644. doi: https://doi.org/10.7326/0003-4819-75-4-643
Download citation file:
© 2020
Published: Ann Intern Med. 1971;75(4):643-644.
DOI: 10.7326/0003-4819-75-4-643
Gastroenterology/Hepatology, Liver Disease.
Results provided by: